India Diabetes Drugs and Devices Market Size (2024 - 2029)

India Diabetes Drugs and Devices Market Analysis

India's diabetes care drugs and devices market size is estimated at USD 3.8 billion in the current year. The market is expected to reach USD 4.4 billion in five years, registering a CAGR of more than 3% during the forecast period.

In India, the COVID-19 outbreak began nearly two years ago and has increased by nearly 25%. With over 80 million diabetics, India is called the Diabetes Capital. COVID-19 is a viral infection that causes various inflammatory responses and is associated with several recurring and emerging health problems, including hypoxia, wasting, weight loss, hair loss, myocarditis, and thyroid problems. Increase. However, diabetes is one of the most common side effects of infections. Anoop Misra, a senior endocrinologist in Delhi, observed the prevalence of new-onset diabetes and thyroid dysfunction in patients with COVID-19 in all countries; He said the explanations included the severe effects of a cytokine surge (the strong immune responses reported in certain COVID-19 patients) and some development of autoimmunity (the body's immune system goes awry and when it affects the tissues and organs of the body), it was speculated that it might be included.

A review of literature from around the world finds that metformin is used in various ways in the early stages of diabetes. Sharma et al. found a changing trend in 55% of metformin-treated individuals. The fraction of individuals on metformin remains stable from 0 to 20 years of diabetes. The proportion of sulfonylurea and dipeptidyl peptidase-4 inhibitors (DPP4i) increases from 23.12% and 22.5% in 0-5 years of diabetes to 70.77% and 60% in 10-15 years of diabetes. Following that, the proportion of sulfonylurea and DPP4i remains constant. As the use of sulfonylureas and DPP4i reaches a plateau, insulin and sodium/glucose cotransporter two inhibitors increase. From 5 to 10 years of diabetes duration to 20+ years of diabetes duration, the proportion of alpha-glucosidase inhibitors increases somewhat. Thiazolidinediones and glucagon-like peptide-1 receptor agonists have a small proportion in contemporary practice and the given patient population.

Thus, the above factors are expected to drive the market growth over the forecast period.

India Diabetes Drugs and Devices Industry Segmentation

Patients with type 1 diabetes must be given insulin because their pancreas cannot process it. To control blood sugar levels, insulin must be given several times a day, such as when eating or drinking. Many people with type 2 diabetes also need to take antidiabetic drugs. These drugs include diabetes medications and injections, such as insulin. The India diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), and devices (management devices such as insulin pumps, insulin pens, syringes, cartridges, and jet injectors, and monitoring devices including self-monitoring blood and continuous glucose monitoring). The report offers the value (in USD) and volume (in unit) for the above segments.